FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896726286> ?p ?o ?g. }

• W2896726286 abstract "The PharE Study (Pharmacovigilance in the Elderly) is an ongoing study on elderly home care and residential care patients affected with dementia. Antipsychotic drugs are approved for a range of psychiatric disorders, but they are also widely prescribed for control of behavioral and psychological symptoms of dementia (BPSD). Clinical studies with antipsychotic drugs showed small but statistically significant improvements in BPSD compared with placebo, but the treatment was associated with an increased risk for adverse events, such as cardiovascular, cerebrovascular events and death. This was a retrospective study between 2015 and 2017. In this time range 2064 visits were performed by our center in residential and home care patients. In particular, the study included 688 patients affected with dementia, mean age 80.6±7.05 years old, 424 women and 264 men; 144 residential care patients and 544 home care patients. The 2015 updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults were used. The primary outcomes were to assess the rate of deprescribing antipsychotics in both care settings. The secondary outcomes were to assess the possible side effects or adverse events in antipsychotics users vs non users and to identify the possible inappropriate use of these drugs. BPSD rate was high (48.8%), with an antipsychotic use of 87.8%. The rate of deprescribing antipsychotics was 8.1% in home care patients and 3.5% in residential care patients. There was a significant difference in deprescribing between the two different settings (p<0.04). Antipsychotics were administered for 19.8 ± 9.8 months on the average. Side effects and adverse events were more frequent in antipsychotic users vs non users (p=0.0000). Inappropriate use of antipsychotics according to the 2015 Beers Criteria was found in 9.3% out of the cases. Antipsychotics should be avoided for BPSD unless non-pharmacologic options have failed, or the patient is threatening self-harm or harm to others. In order to use these drugs appropriately, we should ask why the patient is taking the drug, whether it was appropriate initially, and whether it is still needed. A 25%-50% dose reduction is suggested every 1-2 weeks. Further details on this topic are strongly recommended." @default.
• W2896726286 created "2018-10-26" @default.
• W2896726286 creator A5024765683 @default.
• W2896726286 creator A5080214769 @default.
• W2896726286 creator A5080237017 @default.
• W2896726286 creator A5090988550 @default.
• W2896726286 date "2018-07-01" @default.
• W2896726286 modified "2023-10-16" @default.
• W2896726286 title "P4‐208: DEPRESCRIBING ANTIPSYCHOTICS IN DEMENTIA: A FEASIBLE WAY TO TREAD? TIPS FROM THE PHARE STUDY" @default.
• W2896726286 doi "https://doi.org/10.1016/j.jalz.2018.07.029" @default.
• W2896726286 hasPublicationYear "2018" @default.
• W2896726286 type Work @default.
• W2896726286 sameAs 2896726286 @default.
• W2896726286 citedByCount "0" @default.
• W2896726286 crossrefType "journal-article" @default.
• W2896726286 hasAuthorship W2896726286A5024765683 @default.
• W2896726286 hasAuthorship W2896726286A5080214769 @default.
• W2896726286 hasAuthorship W2896726286A5080237017 @default.
• W2896726286 hasAuthorship W2896726286A5090988550 @default.
• W2896726286 hasConcept C118552586 @default.
• W2896726286 hasConcept C126322002 @default.
• W2896726286 hasConcept C177713679 @default.
• W2896726286 hasConcept C194828623 @default.
• W2896726286 hasConcept C197934379 @default.
• W2896726286 hasConcept C2776412080 @default.
• W2896726286 hasConcept C2776484012 @default.
• W2896726286 hasConcept C2779134260 @default.
• W2896726286 hasConcept C2779483572 @default.
• W2896726286 hasConcept C2780494398 @default.
• W2896726286 hasConcept C36434225 @default.
• W2896726286 hasConcept C71924100 @default.
• W2896726286 hasConceptScore W2896726286C118552586 @default.
• W2896726286 hasConceptScore W2896726286C126322002 @default.
• W2896726286 hasConceptScore W2896726286C177713679 @default.
• W2896726286 hasConceptScore W2896726286C194828623 @default.
• W2896726286 hasConceptScore W2896726286C197934379 @default.
• W2896726286 hasConceptScore W2896726286C2776412080 @default.
• W2896726286 hasConceptScore W2896726286C2776484012 @default.
• W2896726286 hasConceptScore W2896726286C2779134260 @default.
• W2896726286 hasConceptScore W2896726286C2779483572 @default.
• W2896726286 hasConceptScore W2896726286C2780494398 @default.
• W2896726286 hasConceptScore W2896726286C36434225 @default.
• W2896726286 hasConceptScore W2896726286C71924100 @default.
• W2896726286 hasIssue "7S_Part_29" @default.
• W2896726286 hasLocation W28967262861 @default.
• W2896726286 hasOpenAccess W2896726286 @default.
• W2896726286 hasPrimaryLocation W28967262861 @default.
• W2896726286 hasRelatedWork W1972059815 @default.
• W2896726286 hasRelatedWork W2021673836 @default.
• W2896726286 hasRelatedWork W2034989789 @default.
• W2896726286 hasRelatedWork W2071983500 @default.
• W2896726286 hasRelatedWork W2470111852 @default.
• W2896726286 hasRelatedWork W2885375796 @default.
• W2896726286 hasRelatedWork W2962135387 @default.
• W2896726286 hasRelatedWork W2982126825 @default.
• W2896726286 hasRelatedWork W3006205584 @default.
• W2896726286 hasRelatedWork W3216642618 @default.
• W2896726286 hasVolume "14" @default.
• W2896726286 isParatext "false" @default.
• W2896726286 isRetracted "false" @default.
• W2896726286 magId "2896726286" @default.
• W2896726286 workType "article" @default.